公开(公告)号：BG65261B1

公开(公告)日：2007-10-31

申请号：BG10552301

申请日：2001-05-19

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL ,  LIU HUAQING ,  MCCARTY CATHERINE ,  PATEL MEENA ,  ROHDE JEFFREY ,  COGHLAN MICHAEL ,  STEWART ANDREW

IPC: C07D237/14 ,  A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: The present invention describes pyridazoline compounds of formula which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX 2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COC-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal(GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marked non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：BG64675B1

公开(公告)日：2005-11-30

申请号：BG10424100

申请日：2000-03-15

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL ,  LIU HUAQING ,  MCCARTY CATHERINE ,  PATEL MEENA ,  RHODE JEFFREY

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

Abstract: The pyridazinon compounds are selective inhibitors of cyclooxygenase (COX), in particular of cyclooxygenase-2 (COX/2), COX-2 - inducible isoform which is related to the respective inflammation, as opposite to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important enzyme in many tissues, including the gastrointestinal tract and in the kidneys. The selectivity of the COX-2 compounds reduces to a minimum the unwanted side effects in the gastrointestinal tract and in the kidneys observed in the so-far knowm nonsteroid antiphlogistic medicaments.